About The Study: In participants with type 2 diabetes inadequately controlled by insulin glargine, addition of oral orforglipron significantly improved glycemic control and body weight, without increasing hypoglycemia risk, compared with placebo. Orforglipron is an oral, nonpeptide glucagon-like peptide 1 (GLP-1) receptor agonist.
Corresponding Author: To contact the corresponding author, Francesco Giorgino, MD, email francesco.giorgino@uniba.it .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2026.9512)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the 2026 American Diabetes Association’s Scientific Sessions.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.9512?guestAccessKey=0bc5930a-69a4-4659-89c3-2a73cde7550f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060726
JAMA